Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

被引：40

作者：

Gassanov, Natig ^{[1
]}

Semmo, Nasser ^{[2
]}

Semmo, Mariam ^{[3
]}

Nia, Amir M. ^{[1
]}

Fuhr, Uwe ^{[4
]}

Er, Fikret ^{[1
]}

机构：

[1] Univ Cologne, Dept Internal Med 3, D-50937 Cologne, Germany

[2] Univ Hosp Freiburg, Dept Med 2, Freiburg, Germany

[3] Univ Hosp Freiburg, Dept Nephrol, Freiburg, Germany

[4] Univ Cologne, Dept Pharmacol, D-50937 Cologne, Germany

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 67卷 / 04期

关键词：

Vasopressin; Vaptans; Hyponatremia; Heart failure; SIADH; LEFT-VENTRICULAR DYSFUNCTION; PLACEBO-CONTROLLED TRIAL; V-2-RECEPTOR ANTAGONIST; ORAL TOLVAPTAN; SERUM SODIUM; DOUBLE-BLIND; INTRAVENOUS CONIVAPTAN; HYPONATREMIC PATIENTS; SYSTOLIC DYSFUNCTION; ENDOTHELIAL-CELLS;

D O I：

10.1007/s00228-011-1006-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V1aR-mediated vasoconstriction and V2R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.

引用

页码：333 / 346

页数：14

共 79 条

[1] Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study [J].

Abraham, William T. ;

Aranda, Juan M. ;

Boehmer, John P. ;

Elkayam, Uri ;

Gilbert, Edward M. ;

Gottlieb, Stephen S. ;

Hasenfuss, Gerd ;

Kukin, Marrick ;

Lowes, Brian D. ;

O'Connell, John B. ;

Tavazzi, Luigi ;

Feldman, Arthur M. ;

Ticho, Barry ;

Orlandi, Cesare .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2010, 3 (05) :249-253

[2] Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients [J].

Abraham, WT ;

Shamshirsaz, AA ;

McFann, K ;

Oren, RM ;

Schrier, RW .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) :1615-1621

[3] 5-fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985):: An orally active arginine vasopressin antagonist with selectivity for V2 receptors [J].

Albright, JD ;

Reich, MF ;

Delos Santos, EG ;

Dusza, JP ;

Sum, FW ;

Venkatesan, AM ;

Coupet, J ;

Chan, PS ;

Ru, X ;

Mazandarani, H ;

Bailey, T .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (14) :2442-2444

[4] Therapeutic potential of vasopressin receptor antagonists [J].

Ali, Farhan ;

Guglin, Maya ;

Vaitkevicius, Peter ;

Ghali, Jalal K. .

DRUGS, 2007, 67 (06) :847-858

[5] SYSTEMIC AND REGIONAL EFFECTS OF VASOPRESSIN AND ANGIOTENSIN IN ACUTE LEFT-VENTRICULAR FAILURE [J].

ARNOLDA, L ;

MCGRATH, BP ;

JOHNSTON, CI .

AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (02) :H499-H506

[6] The syndrome of inappropriate antidiuretic hormone secretion [J].

Baylis, PH .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (11) :1495-1499

[7] A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis [J].

Berghmans, T ;

Paesmans, M ;

Body, JJ .

SUPPORTIVE CARE IN CANCER, 2000, 8 (03) :192-197

[8] Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia [J].

Berl, Tomas ;

Quittnat-Pelletier, Friederike ;

Verbalis, Joseph G. ;

Schrier, Robert W. ;

Bichet, Daniel G. ;

Ouyang, John ;

Czerwiec, Frank S. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (04) :705-712

[9]

Bernat A, 1997, J PHARMACOL EXP THER, V282, P597

[10] ROLE OF VASOPRESSIN IN ABNORMAL WATER-EXCRETION IN CIRRHOTIC-PATIENTS [J].

BICHET, D ;

SZATALOWICZ, V ;

CHAIMOVITZ, C ;

SCHRIER, RW .

ANNALS OF INTERNAL MEDICINE, 1982, 96 (04) :413-417

← 1 2 3 4 5 6 7 8 →